<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel>
<title><![CDATA[Chinese Herbal Medicines -->Early Online Releases]]></title>
<item>
<title><![CDATA[Clinical study on the combination of Brucea javanica oil emulsion injection and CapeOx regimen in the treatment of early-onset colon cancerGuan Heyan 1, 2 Wang Lu 1, Liang Xuyang 1, Ren Ling 1, Lv Shengxiang 1*]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202309220000002]]></link>
<description><![CDATA[Objective: To explore the clinical efficacy of Brucea javanica oil emulsion injection combined with CapeOx regimen (i.e. capecitabine+oxaliplatin) in the treatment of early-onset colon cancer. Method: 96 patients with early-onset colon cancer admitted to our hospital from June 2017 to May 2021 were randomly divided into two groups using a random number table method. The control group was treated with CapeOx regimen chemotherapy, and on this basis, the treatment group was combined with Brucea javanica oil emulsion injection for treatment. After two cycles, the short-term efficacy of the two groups was evaluated. Compare the levels of serum tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19 9, CA72-4, CA50], vascular endothelial growth factor (VEGF), and quality of life assessment scale (FACT-C) scores of colorectal cancer patients before and after treatment between the two groups. Count the adverse reactions in both groups. Compared with the control group [35.42% (17/48) and 70.83% (34/48)], the objective response rate [47.92% (23/48)] in the treatment group was improved, but the difference was not statistically significant (P>0.05). The disease control rate [87.50% (42/48)] in the treatment group was significantly increased (P<0.05). After treatment, the serum levels of CEA, CA19-9, CA72-4, CA50, and VEGF in both groups significantly decreased (P<0.05), with the treatment group being the most prominent (P<0.05). After treatment, the physiological status, emotional status, additional focus area scores, and total score of the FACT-C scale in both groups significantly increased (P<0.05), with the treatment group being the most prominent (P<0.05); There was no statistically significant difference in the scores of functional status and social/family status within the group before and after treatment, as well as between groups during the same period (P>0.05). The incidence of leukopenia, liver and kidney damage, and thrombocytopenia in the treatment group was 18.75% (9/48), 10.42% (5/48), and 14.58% (7/48), respectively, significantly lower than 37.50% (18/48), 27.08% (13/48), and 33.33% (16/48) in the control group (P<0.05); There was no statistically significant difference in the incidence of other adverse reactions between the two groups (P>0.05). Conclusion: Combining the CapeOx regimen with Brucea javanica oil emulsion injection in the treatment of early-onset colon cancer has a certain synergistic and detoxifying effect, which can effectively improve the short-term efficacy, lower the level of tumor markers in the blood, inhibit tumor angiogenesis, and improve chemotherapy tolerance, thus improving the quality of life of patients.
Keywords: Early onset colon cancer; Chemotherapy; Brucea javanica oil emulsion injection; Tumor markers; vascular endothelial growth factor]]></description>
<pubDate>2023/10/29 13:11:35</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[管河延,梁旭阳,吕胜祥,任玲,王璐]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on the Treatment of Oral Ulcers with Compound Pearl Aphthous Granules Combined with Kangfu Xin LiquidLi Fang1, Sun Yan2*]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202309170000002]]></link>
<description><![CDATA[Objective: To investigate the clinical efficacy of compound pearl aphthous granules combined with Kangfu Xin liquid in the treatment of oral ulcers.Methods: A total of 96 patients with oral ulcers admitted to our hospital from July 2020 to June 2023 were randomly divided into two groups. The control group received treatment with Kangfu Xin liquid gargle, while the treatment group received oral treatment with compound pearl aphthous granules in addition to Kangfu Xin liquid gargle. The efficacy, pain relief, and ulcer healing time were observed after a 1-week treatment course. The visual analogue scale (VAS) for pain, 14-item Oral Health Impact Profile (OHIP-14), Symptom Checklist-90 (SCL-90) scores, as well as serum interleukin-17 (IL-17), complement C3 and C4, superoxide dismutase (SOD), and transforming growth factor-beta (TGF-β) levels were compared before and after treatment. Adverse reactions in both groups were also recorded.Results: The total effective rate in the treatment group [97.92% (47/48)] was significantly higher than that in the control group [83.33% (40/48)] (P<0.05). The pain relief time and ulcer healing time in the treatment group were significantly shorter than those in the control group (P<0.05). After treatment, both groups showed significant reductions in pain VAS, OHIP-14, and SCL-90 scores (P<0.05), with greater reductions observed in the treatment group (P<0.05). After treatment, the serum IL-17 levels in both groups significantly decreased (P<0.05), while serum complement C3, C4, SOD, and TGF-β levels significantly increased (P<0.05), with greater increases observed in the treatment group (P<0.05). The incidence of adverse reactions in the treatment group [2.08% (1/48)] was not significantly different from that in the control group [0 (0/48)] (P>0.05).Conclusion: Compound pearl aphthous granules combined with Kangfu Xin liquid is an ideal treatment option for oral ulcers, as it effectively promotes pain relief and ulcer healing, regulates immune disorders and inflammatory responses, and significantly improves patient recovery, psychological state, and quality of life.]]></description>
<pubDate>2023/10/29 13:11:35</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[黎芳,孙燕]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on the Treatment of Ankle Arthritis with Gutongling Tincture and Sodium Hyaluronate]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202310090000034]]></link>
<description><![CDATA[Objective: To explore the clinical efficacy of Gutongling Tincture combined with sodium hyaluronate in the treatment of ankle arthritis. Method: 82 patients with ankle arthritis admitted to our hospital from June 2020 to May 2023 were selected and evenly divided into two groups using a random number table method. The control group was treated with intra-articular injection of sodium hyaluronate injection, and on this basis, the treatment group was treated with hot compress of Gutongling Tincture for 12 weeks. Observe the clinical efficacy of two groups and compare the ankle joint swelling score, pain visual analogue scale (VAS) score, morning stiffness time, Kofoed ankle joint function score, AOFAS ankle and hind foot function score, 36 health survey summary (SF-36) score, and serum transforming growth factor before and after treatment- β 1 (TGF- β 1) Horizontal. Count the adverse reactions in both groups. Compared with the control group [80.49% (33/41)], the total effective rate of the treatment group [95.12% (39/41)] was significantly improved (P<0.05). After treatment, the swelling score and pain VAS score of both groups were significantly reduced (P<0.05), and the morning stiffness time was significantly shortened (P<0.05), especially in the treatment group (P<0.05). After treatment, the pain, function, range of motion scores, and total scores in the Kofoed ankle joint function scores of both groups significantly increased (P<0.05), with the treatment group being the most prominent (P<0.05). After treatment, both AOFAS ankle and hind foot function scores, SF-36 scores, and serum TGF were significantly increased in both groups (P<0.05)- β All levels significantly decreased (P<0.05), with the treatment group being the most prominent (P<0.05). The adverse reaction rate in the treatment group [9.76% (4/41)] was higher than that in the control group [4.88% (2/41)], with no statistically significant difference (P>0.05). Conclusion: The combination of Gutongling tincture and sodium hyaluronate in the treatment of ankle arthritis has better efficacy and safety. It can effectively alleviate clinical symptoms, improve ankle function, and improve quality of life in patients, and downregulate serum TGF- β 1 expression promotes remission of the condition.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[王利君]]></author>
</item>
<item>
<title><![CDATA[Clinical study of rotigotine patch combined with amantadine in the treatment of parkinson's disease]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202212070000022]]></link>
<description><![CDATA[[Abstract] Objective To investigate the clinical efficacy of rotigotine patch combined with amantadine in the treatment of Parkinson's disease. Methods 124 patients with Parkinson's disease admitted to Bayan Nur Hospital outpatients and inpatients from November 2019 to December 2021 were randomly divided into two groups. The control group was treated with amantadine hydrochloride tablets. On this basis, the treatment group was treated with rotigotine patch, and the efficacy of the two groups was evaluated after 12 weeks of continuous use. The scores of the unified Parkinson's Disease Rating Scale (UPDRS), the Psychosocial Adaptation Scale (PAS), the Parkinson's Sleep Scale-2 (PDSS-2), the eight item Parkinson's Disease Questionnaire (PDQ-8), the Parkinson's Disease Non motor Symptom Scale (PD-NMSS), and the levels of serum superoxide dismutase (SOD), acetylcholine (Ach), and interleukin-6 (IL-6) were compared between the two groups before and after treatment. The side effects of the two groups were counted. Results Compared with the control group, the effective rate [80.65% (50/62)] was significantly higher in the treatment group [93.55% (58/62)] (P<0.05). After treatment, the scores of part I, II, III and IV of UPDRS and the total score of the scale in both groups were significantly lower than those before treatment (P<0.05), especially in the treatment group (P<0.05). After treatment, PAS scores in both groups were significantly increased (P<0.05), while PDSS-2, PDQ-8, PD-NMSS scores were significantly decreased (P<0.05), and the improvement was more significant in the treatment group (P<0.05). After treatment, the levels of serum SOD in both groups were significantly higher than those before treatment (P<0.05), and the levels of serum Ach and IL-6 were significantly lower than those before treatment (P<0.05); After treatment, the level of serum SOD in the treatment group was significantly higher than that in the control group (P<0.05), and the level of serum Ach and IL-6 was significantly lower than that in the control group (P<0.05). The adverse reaction rate in the treatment group was 11.29% (7/62), which was no significant difference compared with the control group [8.06% (5/62)] (P>0.05). Conclusion Rotigotine patch combined with amantadine in the treatment of Parkinson's disease can achieve a definite effect, and can effectively improve the clinical symptoms, sleep status and quality of life of patients, and can further enhance the antioxidant capacity of the body, reduce inflammatory damage and inhibit the hyperactivity of Ach, which is conducive to delaying the progress of the disease with good safety.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[丁姝月]]></author>
</item>
<item>
<title><![CDATA[Clinical Study of Xinxuening Tablets Combined with Valsartan and chlorothiazide in the Treatment of Essential Hypertension]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202304170000010]]></link>
<description><![CDATA[[Abstract] Objective To explore the clinical efficacy of Xinxuening Tablet combined with valsartan and hydrochlorothiazide in the treatment of essential hypertension. Method: 116 patients with primary hypertension admitted to our hospital from March 2021 to March 2022 were selected and evenly divided into two groups using a random number table method. The control group was treated with valsartan and chlorothiazide tablets. On this basis, the treatment group was treated with Xinxuening tablets. After 12 weeks of treatment, the efficacy and disappearance rate of main symptoms of the two groups were observed. Compare the systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour ambulatory blood pressure indicators, as well as the scores of the Duchenne Hypertension Quality of Life Scale and the World Health Organization Quality of Life Checklist (WHO QOL BREF) before and after treatment between the two groups. Calculate the side effects related to two groups of drugs. Compared with the control group [86.21% (50/58)], the total effective rate of the treatment group [96.55% (56/58)] was significantly improved (P<0.05). After treatment, the SBP, DBP, and 24-hour ambulatory blood pressure indicators [24hSBP, 24hDBP, daytime SBP (dSBP), daytime DBP (dDBP), nighttime SBP (nSBP), nighttime DBP (nDBP), 24-hour mean arterial pressure (24hMAP), 24-hour SBP coefficient of variation (24hSBPCV), and 24-hour DBPCV] in both groups significantly decreased compared to before treatment (P<0.05), while the Du's Hypertension Quality of Life Scale and WHOQOL-BREF scores significantly increased compared to before treatment (P<0.05); After treatment, the SBP, DBP, and 24-hour ambulatory blood pressure indicators (24h SBP, 24h DBP, dSBP, dDBP, nSBP, nDBP, 24h MAP, 24h SBPCV, 24h DBPCV) in the treatment group were significantly lower than those in the control group (P<0.05), and the scores on the Du's Hypertension Quality of Life Scale and WHOQOL-BREF were significantly higher than those in the control group (P<0.05). After treatment, the disappearance rates of dizziness, headache, and chest tightness in the treatment group [94.83% (55/58), 89.66% (52/58), 79.31% (46/58)] were significantly higher than those in the control group [86.21% (50/58), 75.86% (44/58), 62.07% (36/58), P<0.05]. The adverse reaction rate in the treatment group [5.17% (3/58)] was higher than that in the control group [3.45% (2/58)], with no statistically significant difference (P>0.05). Conclusion The combined use of Xinxuening Tablets and valsartan hydrochlorothiazide in patients with essential hypertension has a definite overall effect, which can effectively achieve stable control of blood pressure and significant relief of symptoms, and promote the improvement of patients' quality of life.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[Liu Fang,Ma honghong,zhangxiaoming]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on the Combination of Baohe Pill and Compound Digestive Enzyme in the Treatment of Functional DyspepsiaTan Yang, Zhao Li, Yang Liu*]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202304180000036]]></link>
<description><![CDATA[Objective: To explore the clinical efficacy of Baohe Pill combined with compound digestive enzymes in the treatment of functional dyspepsia. Method: 78 patients with functional dyspepsia admitted to our hospital from January 2018 to December 2022 were selected and randomly divided into two groups. The control group was treated with compound digestive enzyme capsules, and on this basis, the treatment group was combined with Baohe Pills for treatment. After a 4-week course of treatment, the therapeutic effects of the two groups were observed. Compare the main symptom scores, Functional Dyspepsia Quality of Life Scale (FDDQL) scores, Simple Nippon Dyspepsia Index (SF-NDI) scores, and gastric emptying indicators between the two groups before and after treatment. Calculate the side effects related to two groups of drugs. Compared with the control group [79.49% (31/39)], the total effective rate of the treatment group [97.44% (38/39)] was significantly improved (P<0.05). After treatment, the scores and total scores of postprandial fullness, discomfort, upper abdominal pain, early satiety, and upper abdominal burning sensation in both groups were significantly reduced compared to before treatment (P<0.05), especially in the treatment group (P<0.05). After treatment, the FDDQL scores of both groups significantly increased compared to before treatment (P<0.05), while the SF-NDI scores significantly decreased compared to before treatment (P<0.05). The gastric emptying time was significantly shortened compared to before treatment (P<0.05), and the amplitude and frequency of gastric antrum contraction were significantly increased compared to before treatment (P<0.05); After treatment, the FDDQL score of the treatment group was significantly higher than that of the control group (P<0.05), the SF-NDI score was significantly lower than that of the control group (P<0.05), the gastric half emptying time was significantly shorter than that of the control group (P<0.05), and the amplitude and frequency of gastric antrum contraction were significantly higher than those of the control group (P<0.05). The adverse reaction rate in the treatment group [5.13% (2/39)] was not statistically significant compared to the control group [2.56% (1/39)] (P>0.05). Conclusion: The combination of Baohe Pill and Compound Digestive Enzyme has a definite overall therapeutic effect on functional dyspepsia, which can safely and effectively alleviate patients' symptoms, promote gastric emptying, and improve quality of life.
Keywords: Functional dyspepsia; Baohe Pill; Compound digestive enzyme; Quality of life; Gastric motility]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[谭扬,杨柳,赵丽]]></author>
</item>
<item>
<title><![CDATA[Clinical Study of Bailing Capsules Combined with Hydroxychloroquine in the Treatment of Primary IgA NephropathySKong Lin, Chen Xinzheng, Sun Chen, Ma Hao Wang Chunli *]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202304250000001]]></link>
<description><![CDATA[Department of Nephrology, Baoji Hospital of Traditional Chinese medicine, Shaanxi Baoji 721000 communication by Wang Chunli, Email: Wangchunli666@163. ComObjective To observe the clinical efficacy of Bailing capsule combined with hydroxychloroquine in the treatment of primary IgA nephropathy. Methods A total of 92 patients with primary IgA nephropathy who were admitted to our hospital from August 2019 to July 2021 were selected and divided into two groups according to the random number table method. The control group was treated with hydroxychloroquine sulfate tablets orally, and on this basis, the treatment group was treated with Bailing Capsules orally. After 12 weeks of continuous treatment, the curative effects of the two groups were evaluated. The main symptom scores, renal function indexes, serum interleukin (IL)-17, IL-23, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor-β1 (TGF-β1) were compared between the two groups before and after treatment. ) and matrix metalloproteinase-9 (MMP-9) levels. The side effects of the two groups were counted. Results The total effective rate in the treatment group was 95.7% (44/46), which was significantly higher than that in the control group [82.6% (38/46), P<0.05]. Compared with before treatment, the scores of the main symptoms (hematuria, foamy urine, swelling of the face, swollen limbs, and weak waist and knees) in the two groups were significantly decreased after treatment (P<0.05). significantly lower than the control group (P<0.05). After treatment, 24 h UP, serum Cr and BUN levels in both groups were significantly decreased compared with those before treatment (P<0.05); and the improvement in the treatment group was more significant (P<0.05). Compared with before treatment, the serum levels of IL-17, IL-23, MCP-1, TGF-β1 and MMP-9 in the two groups were significantly decreased after treatment (P<0.05); and the decrease in the treatment group was more significant (P<0.05). P<0.05). The adverse reaction rate in the treatment group [13.0% (6/46)] was not significantly different from that in the control group [10.9% (5/46)] (P>0.05). Conclusion Bailing Capsules combined with hydroxychloroquine has a definite overall curative effect in the treatment of primary IgA nephropathy, can effectively relieve the clinical symptoms of patients, protect renal function, and further down-regulate IL-17, IL-23, MCP-1, TGF-β1 and renal function in vivo. The expression level of MMP-9 is beneficial to reduce the inflammatory injury of the patient"s body, inhibit tissue fibrosis, and has good safety.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[陈新政,孔琳,马浩,孙晨,王春丽]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on the Treatment of Acute Cerebral Infarction with Naoan Dropping Pills and Butylphthalein Injection]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202305080000007]]></link>
<description><![CDATA[Objective: To explore the clinical efficacy of Naoan Dropping Pills combined with Butylphthalein Injection in the treatment of acute cerebral infarction. Method: 146 patients with acute cerebral infarction admitted to our hospital from January to December 2022 were selected and evenly divided into two groups using a random number table method. The control group was treated with butylphthalide sodium chloride injection, and on this basis, the treatment group was treated with Naoan dripping pills. After 14 days of treatment, the therapeutic effects of the two groups were observed. The scores of the simplified Fugl Meyer Rating Scale (FMA) and the National Institutes of Health Stroke Scale (NIHSS), the parameters of thrombus and platelet, and the levels of serum C-reactive protein (CRP), nitric oxide (NO), superoxide dismutase (SOD), glutamic acid (Glu) were compared between the two groups before and after treatment. Count the adverse reactions in both groups. Compared with the control group [86.30% (63/73)], the total effective rate of the treatment group [95.89% (70/73)] was significantly improved (P<0.05). After treatment, the FMA score, serum NO and SOD levels in both groups were significantly increased compared with those before treatment (P<0.05), while the NIHSS score, plasma plasmin anti plasmin complex (PAP), thrombin antithrombin complex (TAT), platelet aggregation rate (PAgT), serum CRP and Glu levels were significantly decreased compared with those before treatment (P<0.05); After treatment, the FMA score and serum NO, SOD levels in the treatment group were significantly higher than those in the control group (P<0.05), while the NIHSS score, plasma PAP, TAT levels, PAgT, and serum CRP, Glu levels were significantly lower than those in the control group (P<0.05). The adverse reaction rate in the treatment group [6.85% (5/73)] was higher than that in the control group [5.48% (4/73)], with no statistically significant difference (P>0.05). Conclusion: The application of Naoan Dropping Pills combined with Butylphthalein Injection in the treatment of acute cerebral infarction patients can achieve good therapeutic effects, effectively resist thrombosis, reduce inflammation and oxidative stress damage, promote the improvement of neurological deficits and motor function recovery, and have good safety.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[吴延华]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on Tongxuan Lifei Granule Combined with Cefprozil in Treating Children with Acute Upper respiratory tract infection]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202306220000005]]></link>
<description><![CDATA[[Abstract] Objective To explore the clinical efficacy of Tongxuan Lifei Granule combined with Cefprozil in the treatment of children's acute Upper respiratory tract infection (referred to as children's acute upper respiratory tract infection). Method: 226 children with acute upper respiratory tract infections admitted to our hospital from January 2021 to October 2022 were selected and evenly divided into two groups using a random number table method. The control group was given Cefprozil dispersible tablets. On this basis, the treatment group was treated with Tongxuan Lifei Granules for 5 days. Observe the clinical efficacy and disappearance time of the main symptoms in both groups. The scores of Children's Sleep Habit Questionnaire (CSHQ), Mental Health Scale for Children and Adolescents (MHS-CA), Children's Quality of Life Scale 4.0 (Peds QLTM4.0), WBC, neutrophil ratio (NEUT%), C-reactive protein (CRP), and Calcitonin (PCT) were compared between the two groups before and after treatment. Count the adverse reactions in both groups. The total effective rate of the treatment group was 96.46% (109/113), significantly higher than that of the control group [88.50% (100/113), P<0.05]. The disappearance time of various main symptoms (fever, cough, sore throat, nasal congestion, and runny nose) in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the CSHQ scores and whole blood WBC, NEUT%, CRP, and PCT levels in both groups were significantly lower than before treatment (P<0.05), while the MHS-CA and Peds QLTM4.0 scores were significantly higher than before treatment (P<0.05); After treatment, the CSHQ score and whole blood WBC, NEUT%, CRP, PCT levels in the treatment group were significantly lower than those in the control group (P<0.05), while the MHS-CA and Peds QLTM4.0 scores were significantly higher than those in the control group (P<0.05). The adverse reaction rate in the treatment group [6.19% (7/113)] was higher than that in the control group [4.42% (5/113)], with no statistically significant difference (P>0.05). Conclusion Tongxuan Lifei Granule combined with Cefprozil can effectively accelerate the disappearance of the main clinical manifestations, inhibit the body infection and inflammatory state, effectively improve the sleep, psychology and quality of life of children with acute Shanggan, and have good overall efficacy and safety.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[艾军,宫文浩,何贤芬,赵洁]]></author>
</item>
<item>
<title><![CDATA[Clinical study of Xiyanping injection combined with imipenem cilastatin sodium in the treatment of severe pneumonia in the elderlyZhangYingchao   TangShujin   WangLIjing  Shanshuxiang]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202306070000009]]></link>
<description><![CDATA[Objective: To explore the clinical efficacy of Xiyanping injection combined with imipenem cilastatin sodium in the treatment of severe pneumonia in the elderly. Method: 96 elderly patients with severe pneumonia admitted to our hospital from April 2021 to March 2023 were selected and evenly divided into two groups using a random number table method. The control group was treated with imipenem cilastatin sodium for injection, and on this basis, the treatment group was treated with Xiyanping injection for 14 days. Observe the clinical efficacy and disappearance time of various clinical manifestations in two groups. The PCRAES score, clinical pulmonary infection score (CPIS), respiratory rate (RR), oxygenation index (OI), peripheral blood neutrophil to lymphocyte ratio (NLR), C-reactive protein (CRP), serum pro Calcitonin (PCT) and interleukin-6 (IL-6) levels were compared between the two groups before and after treatment. Count the adverse reactions in both groups. Compared with the control group [79.17% (38/48)], the total effective rate of the treatment group [93.75% (45/48)] was significantly improved (P<0.05). Cough, fever, chest pain, and lung rales disappeared earlier in the treatment group than in the control group (P<0.05). After treatment, the PCRAES score, CPIS score, RR, peripheral blood NLR, CRP, and serum PCT, IL-6 water levels in both groups were significantly reduced (P<0.05), while OI levels were significantly increased (P<0.05); After treatment, the PCRAES score, CPIS score, RR, peripheral blood NLR, CRP, and serum PCT, IL-6 water levels in the treatment group were significantly lower than those in the control group (P<0.05), while OI was significantly higher than those in the control group (P<0.05). The adverse reaction rate in the treatment group [10.42% (5/48)] was higher than that in the control group [6.25% (3/48)], and the difference was not statistically significant (P>0.05). Conclusion: The combined use of Xiyanping injection and imipenem cilastatin sodium in the treatment of elderly patients with severe pneumonia can effectively promote the relief of symptoms and signs, suppress lung infection and systemic inflammation, improve respiratory function, have better safety, and have a definite therapeutic effect.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[zhangyingchao]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on the Treatment of Children"s Acute Upper respiratory tract infection with Xiaoer Resuqing Oral Liquid and Cycloester Erythromycin]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202306120000001]]></link>
<description><![CDATA[Objective To analyze the clinical efficacy of Errexuqing oral liquid combined with Erythromycin cyclic ester in the treatment of children with acute Upper respiratory tract infection. Methods 116 children with acute Upper respiratory tract infection admitted to our hospital from January to December 2022 were randomly divided into two groups. The control group was treated with cyclic ester Erythromycin dry suspension. On this basis, the treatment group was treated with Xiaoer Resuqing oral liquid for 5 days. Observe the clinical efficacy, complete fever relief time, and other symptom disappearance time of two groups. The scores of CSHQ, ISLQ, WBC, Erythrocyte sedimentation rate and CRP were compared between the two groups before and after treatment. Count the adverse reactions in both groups. Results The total effective rate of the treatment group was 94.83% (55/58), significantly higher than that of the control group [84.48% (49/58), P<0.05]. The complete fever relief time and the disappearance time of other symptoms (nasal congestion, runny nose, swollen tonsils, systemic soreness, sore throat, cough) in the treatment group were significantly faster than those in the control group (P<0.05). After treatment, the CSHQ score and whole blood WBC, ESR, CRP levels in both groups were significantly reduced (P<0.05), while the ISLQ score was significantly increased (P<0.05); And the CSHQ score and whole blood WBC, ESR, CRP levels in the treatment group were significantly lower than those in the control group (P<0.05), while the ISLQ score was significantly higher than those in the control group (P<0.05). The adverse reaction rate in the treatment group [5.17% (3/58)] was higher than that in the control group [3.45% (2/58)], with no statistically significant difference (P>0.05).Conclusion The combination regimen of Errexuqing oral liquid and cyclic ester Erythromycin for children with acute Upper respiratory tract infection is effective, has good anti-inflammatory effect, and is well tolerated by children. It can accelerate the improvement of symptoms and signs of children, and reduce the impact of sleep and quality of life.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[Wang Dan,Wang Wenxiu,Wang Yajun,Xi Lei]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on the Treatment of influenza in Children with Erersuqing Granule and OseltamivirWang Dan, Wang Wenxiu, Wang Yajun, Xilei]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202306130000023]]></link>
<description><![CDATA[Objective To explore the clinical efficacy of children"s Resuqing granule combined with Oseltamivir in the treatment of children"s influenza (influenza for short). Method: 98 influenza patients admitted to our hospital from January to May 2023 were selected and evenly divided into two groups using a random number table method. The control group was treated with oseltamivir phosphate granules, while the treatment group was treated with combination of Xiao"er Resuqing granules for 5 days. Observe the clinical efficacy, complete fever relief time, and disappearance time of influenza like symptoms in two groups. Compare the quality of life scale 4.0 (Peds QLTM 4.0), symptom checklist 90 (SCL-90) scores, blood routine indicators, and C-reactive protein (CRP) levels between the two groups before and after treatment. Count the adverse reactions in both groups. The total effective rate of the treatment group was 95.92% (47/49), significantly higher than that of the control group [83.67% (41/49), P<0.05]. The time of complete antipyretic and disappearance of influenza like symptoms (myalgia, headache, general malaise, cough, Sore throat) in the treatment group were significantly faster than those in the control group (P<0.05). After treatment, the Peds QLTM4.0 score in both groups significantly increased (P<0.05), while the SCL-90 score significantly decreased (P<0.05), with the treatment group being the most prominent (P<0.05). After treatment, lymphocyte count (LYMP #) increased significantly in both groups (P<0.05), while neutrophil count (NEUT #), Monocyte count (MONO #) and CRP level decreased significantly (P<0.05), especially in the treatment group (P<0.05). The adverse reaction rate in the treatment group [6.12% (3/49)] was higher than that in the control group [4.08% (2/49)], with no statistically significant difference (P>0.05). Conclusion The combination treatment scheme of Erer Resuqing Granule and Oseltamivir is effective for children with influenza, with rapid relief of symptoms and better tolerance, which is beneficial to the control of inflammatory reaction, the enhancement of immunity, and the improvement of life quality and psychological status of children.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[王丹,王文秀,王亚君,喜雷]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on Children Resuqing Oral Liquid Combined with Cefotaxime in Treating Children with Acute Upper respiratory tract infection]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202306240000006]]></link>
<description><![CDATA[Objective To explore the clinical efficacy of Erersuqing oral liquid combined with Cefotaxime in the treatment of children with acute Upper respiratory tract infection. Methods 84 children with acute Upper respiratory tract infection admitted to our hospital from January 2020 to December 2022 were randomly divided into two groups. The control group was treated with Cefotaxime for injection. On this basis, the treatment group was treated with Xiaoer Resuqing oral liquid for 4 days. Observe the antipyretic effect and clinical symptom disappearance time of two groups. The whole blood lymphocyte to Monocyte ratio (LMR), neutrophil to lymphocyte ratio (NLR), high-sensitivity C-reactive protein (hs CRP) and serum pro Calcitonin (PCT) levels were compared between the two groups before and after treatment. Count the adverse reactions in both groups. The total effective rate of the treatment group was 95.24% (40/42), significantly higher than that of the control group [80.95% (34/42), P<0.05]. The temperature recovery time and antipyretic onset time in the treatment group were significantly shorter than those in the control group (P<0.05); The immediate fever reduction rate in the treatment group was 52.38% (22/42), significantly higher than that in the control group [30.95% (13/42), P<0.05]. The disappearance time of clinical symptoms (nasal congestion, runny nose, cough, sore throat) in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the whole blood LMR levels in both groups significantly increased compared to before treatment (P<0.05), while the whole blood NLR, hs CRP, and serum PCT levels significantly decreased compared to before treatment (P<0.05); After treatment, the whole blood LMR levels in the treatment group were significantly higher than those in the control group (P<0.05), while the whole blood NLR, hs CRP, and serum PCT levels were significantly lower than those in the control group (P<0.05). The adverse reaction rate in the treatment group [7.14% (3/42)] was higher than that in the control group [4.76% (2/42)], with no statistically significant difference (P>0.05). Conclusion The combination of Erersuqing oral liquid and Cefotaxime in the treatment of children with acute Upper respiratory tract infection can effectively shorten the recovery time of symptoms and signs, inhibit the inflammatory state of the body, and has better safety.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[fengdandan,jiangrongrong,shicheng,wumenghua]]></author>
</item>
<item>
<title><![CDATA[Clinical Study on Liuwei Dihuang Pill Combined with Enggligin in the Treatment of Type 2 diabetes]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202309230000002]]></link>
<description><![CDATA[[Abstract] Objective To explore the clinical effect of Liuwei Dihuang Pill combined with Enggligin in the treatment of type 2 diabetes. Methods The data of 102 patients with type 2 diabetes admitted to our hospital from March 2020 to February 23 were retrospectively analyzed. They were divided into control group and treatment group according to different treatment schemes, with 51 cases in each group. The control group was treated with Engliflozin, while the treatment group was treated with Liuwei Dihuang Wan combined with Engliflozin for 12 weeks. Observe the hypoglycemic efficacy of two groups. The blood glucose indexes, islet function related indexes, quality of life scale (DMQLS) score, neutrophil lymphocyte ratio (NLR), serum triglyceride (TG), total cholesterol (TC), apoA1, and feeding inhibitory factor-1 (Nesfatin-1) were compared between the two groups before and after treatment. Count the adverse reactions in both groups. Compared with the control group [82.35% (42/51)], the total effective rate of hypoglycemia in the treatment group [96.08% (49/51)] was significantly increased (P<0.05). After treatment, the fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, insulin resistance index, and DMQLS score of both groups were significantly reduced compared to before treatment (P<0.05), and the quantitative insulin sensitivity index was significantly higher than before treatment (P<0.05), with the treatment group being the most prominent (P<0.05). After treatment, the whole blood NLR and serum TG, TC, and Nesfatin-1 levels in both groups were significantly lower than before treatment (P<0.05), and the serum ApoA1 level was significantly higher than before treatment (P<0.05), with the treatment group being the most prominent (P<0.05). The adverse reaction rate in the treatment group [5.88% (3/51)] was not statistically significant compared to the control group [3.92% (2/51)] (P>0.05). Conclusion Liuwei Dihuang Pill combined with Enggligin can achieve satisfactory results in the treatment of type 2 diabetes, effectively reduce the inflammatory state of the body, correct the disorder of lipid metabolism, and have prominent effects on the control of blood sugar, the improvement of pancreatic islet function and quality of life of patients.]]></description>
<pubDate>2023/10/29 13:11:28</pubDate>
<category><![CDATA[临床研究]]></category>
<author><![CDATA[liuhuizhong]]></author>
</item>
<item>
<title><![CDATA[Keywords：COVID-19；Fatality rate；Chinese medicine treatment]]></title>
<link><![CDATA[https://www.tiprpress.com/chmen/article/abstract/202003050000048]]></link>
<description><![CDATA[Abstract: To analyze the influencing factors of death in patients with the new coronavirus (COVID-19)and to provide a reference for clinically reducing the mortality of patients with COVID-19.Methods: A retrospective analysis of the case data of all patients with COVID-19 admitted in our hospital from January 8th to February 25th, 2020, and collected the sex, age, whether or not to take Chinese medicine preparations, clinical classification, comorbidities. Nucleic acid test results, admission time, discharge and other relevant indicators for statistical analysis. Results: ①. During the period of COVID-19, the number of patients of COVID-19 in our hospital gradually increased. At the peak period, 904 with COVID-19 patients were treated simultaneously. ②. From January 8th to February 25th, 2020, a total of 1,305 patients with COVID-19 were treated in our hospital, including 632 males and 673 females, and the male to female ratio was 1: 1.06. The age distribution ranged from 7 to 111 years, with a median of 63 (51, 70) years. There was no significant difference in the age distribution of patients between different genders (Z = 1.217, P = 0.224).
③. The results of univariate analysis show that the patient''s gender, age, whether to take Chinese medicine preparations during treatment, clinical typing, whether combined with underlying diseases (hypertension, coronary heart disease, diabetes, tumors and uremia) and nucleic acid test results can all affect patients Fatality rate. ④. Logistics multivariate regression analysis found that taking traditional Chinese medicine preparations, clinical classification, and whether or not underlying diseases were independent risk factors for death in patients with COVID-19。Conclusion: The death of patients with COVID-19 is related to various factors, reducing the occurrence of critical illness, controlling underlying diseases, stabilizing blood pressure and blood sugar, actively improving cardio-cerebral vascular conditions, and stabilizing renal function. Measures, and early application of traditional Chinese medicine treatment also have a very important role in reducing the mortality of patients with COVID-19.]]></description>
<pubDate>2020/3/31 14:28:56</pubDate>
<category><![CDATA[抗新冠肺炎专栏]]></category>
<author><![CDATA[LuoMeng,]]></author>
</item>
</channel>
</rss>